WRBY
Next earnings: Aug 6, 2026 · Before open
Signal
Leaning Bullish1
Price
1
Move-0.59%Quiet session
Volume
1
Volume1.4× avgNormal activity
Technical
1
RSIRSI 58Momentum positive
PRICE
Prev Close
28.90
Open
28.12
Day Range27.77 – 29.28
27.77
29.28
52W Range14.96 – 31.00
14.96
31.00
86% of range
VOLUME & SIZE
Avg Volume
2.9M
FUNDAMENTALS
P/E Ratio
2873.0x
Premium valuation
EPS (TTM)
Div Yield
No dividend
Beta
2.04
High vol
Performance
1D
-0.59%
5D
+6.13%
1M
+21.43%
3M
+27.92%
6M
+69.40%
YTD
+31.85%
1Y
+63.52%
Best: 6M (+69.40%)Worst: 1D (-0.59%)
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +12% YoY · 53% gross margin
Valuation
EXPENSIVE
P/E 2873x vs ~20x sector
Health
STRONG
CR 2.3 · FCF $0.32/sh
Bullish
Key MetricsTTM
Market Cap$3.53B
Revenue TTM$890.57M
Net Income TTM$1.35M
Free Cash Flow$38.90M
Gross Margin53.4%
Net Margin0.2%
Operating Margin-0.7%
Return on Equity0.4%
Return on Assets0.2%
Debt / Equity0.63
Current Ratio2.33
EPS TTM$0.01
Alpha SignalsFull Analysis →
What Moves This Stock

New store opening pace and productivity - investors focus on whether new stores achieve $1M+ annual revenue within 2-3 years

Active customer growth rate - the company's ability to acquire and retain customers across both channels drives lifetime value assumptions

Gross margin trajectory - ability to maintain 55%+ margins while scaling and managing product mix shift toward contacts

Path to profitability - quarterly progress toward sustained positive operating margins and free cash flow generation

Macro Sensitivity
Economic Cycle

moderate - Eyewear purchases are semi-discretionary with medical necessity providing downside protection. While consumers can delay purchases during recessions, vision correction needs create baseline demand. The company's value positioning (vs. $500+ designer frames) may actually benefit during economic stress as consumers trade down from luxury optical retailers. However, discretionary sunglasses and multi-pair purchases decline in downturns. Store traffic and e-commerce conversion rates correlate with consumer confidence and discretionary spending patterns.

Interest Rates

Rising rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting WRBY's 3.3x P/S multiple; (2) Store expansion requires capital investment ($100M annual capex), though the company's strong 2.61 current ratio and minimal debt (0.63 D/E) limit direct financing cost pressure. Consumer financing for eyewear purchases is minimal, so demand-side rate sensitivity is low. The primary impact is valuation multiple compression rather than operational pressure.

Key Risks

Market dominance by EssilorLuxottica (owns LensCrafters, Pearle Vision, Target Optical, Ray-Ban, Oakley) creates competitive challenges and potential supply chain dependencies for certain lens technologies

Vision insurance network dynamics - major insurers (VSP, EyeMed) have relationships with incumbent retailers and may limit Warby Parker's in-network status, forcing customers to pay out-of-pocket

Telehealth and online prescription verification regulations vary by state, potentially limiting e-commerce growth in certain markets

Investor Profile

growth - Investors are attracted to the direct-to-consumer disruption narrative, store expansion opportunity (currently ~250 stores vs. 900+ potential), and path to profitability as the store base matures. The 15.2% revenue growth and improving unit economics appeal to growth investors willing to accept near-term losses for market share gains. Recent 68.5% EPS growth (from deeply negative base) and 30.7% three-month return suggest momentum interest. However, the -10.9% one-year return and high 62.3x EV/EBITDA indicate valuation sensitivity and volatility around execution milestones.

Watch on Earnings
Active customer count and quarterly net additions - primary growth indicatorNew store openings per quarter and average revenue per new store cohort - expansion execution qualityGross margin percentage - ability to maintain pricing power while scalingAdjusted EBITDA and path to positive operating cash flow - profitability inflection timing
Health Radar
3 strong3 concern
43/100
Liquidity
2.33Strong
Leverage
0.63Strong
Coverage
0.0xConcern
ROE
0.4%Concern
ROIC
-0.6%Concern
Cash
$286MStrong
ANALYST COVERAGE14 analysts
BUY
+13.1%upside to target
L $25.00
Med $32.50consensus
H $35.00
Buy
857%
Hold
643%
8 Buy (57%)6 Hold (43%)0 Sell (0%)
Full report →
Stock Health
Composite Score
5 of 5 signals bullish
10/10
Technicals
RSI RangeRSI 58 — Bullish momentum
Volume
Volume FlowAccumulation — institutional buying
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 2.33 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 27, 2026
In 103 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendDeath Cross · 50D trails 200D by 1.5%

+21.8% vs SMA 50 · +20.0% vs SMA 200

Momentum

RSI57.8
Positive momentum, not extended
MACD+1.51
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$31.00+7.9%
Current
$28.73
EMA 50
$24.38-15.1%
EMA 200
$23.63-17.8%
52W Low
$14.96-47.9%
52-Week RangeNear 52-week high
$14.9686th %ile$31.00
Squeeze SetupVolume-based
Moderate Squeeze Setup

Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.

20-Day Money Flow
Acc days:7
Dist days:3
Edge:+4 acc
Volume Context
Avg Vol (50D)2.6M
Recent Vol (5D)
3.5M+33%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 10 analysts
Analyst revisions:Revenue↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2023
$719.9M
$692.4M$785.1M
-$0.39
±8%
High5
FY2024
$768.2M
$767.3M$769.1M
+6.7%$0.24
±4%
High10
FY2025
$874.6M
$872.6M$875.7M
+13.8%$0.37+55.2%
±14%
High8
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryWRBY
Last 8Q
-24.4%avg beat
Beat 3 of 8 quartersMissed 2 Estimates rising
+20%
Q3'24
Q4'24
-67%
Q1'25
Q2'25
Q3'25
+22%
Q4'25
-180%
Q1'26
+9%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
CitigroupMarket Perform → Outperform
Dec 10
UPGRADE
CitigroupNeutral → Market Perform
Jul 10
DOWNGRADE
William BlairOutperform
Nov 7
UPGRADE
Goldman SachsBuy
Oct 21
UPGRADE
JMP SecuritiesOutperform
Aug 22
UPGRADE
Evercore ISIHold → Outperform
Oct 3
UPGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $3.1M sold · 30d window
Singer Bradley EDir
$575K
May 13
SELL
Singer Bradley EDir
$140K
May 14
SELL
Blumenthal Neil Har…CEO
$563K
Apr 20
SELL
Blumenthal Neil Har…CEO
$1.2M
Apr 17
SELL
Blumenthal Neil Har…CEO
$56K
Apr 16
SELL
Blumenthal Neil Har…CEO
$690K
Apr 17
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
FMR LLC
15.5M
2
JPMORGAN CHASE & CO
10.1M
3
BlackRock, Inc.
7.3M
4
Durable Capital Partners LP
6.4M
5
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P.
3.0M
6
STATE STREET CORP
2.4M
7
GEODE CAPITAL MANAGEMENT, LLC
2.4M
8
FULLER & THALER ASSET MANAGEMENT, INC.
2.3M
News & Activity

WRBY News

About

No description available.

Industry
Surgical and Medical Instrument Manufacturing
Neil Harris BlumenthalCo-Founder, President, Co-CEO & Co-Chair
David Abraham GilboaCo-Founder, Co-CEO & Co-Chair
Adrian V. MitchellCFO & Principal Accounting Officer
PeersConsumer Cyclical(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
WRBY
$28.73-0.59%$3.5B+1304.1%18.8%1500
$264.14-1.15%$2.8T31.3+1237.8%1083.4%1521
$422.24-4.75%$1.6T352.3-293.1%400.1%1507
$297.51-2.25%$296.3B20.9+324.0%859.6%1477
$276.39+0.52%$196.4B22.6+372.3%3185.0%1478
$147.43+0.05%$163.2B30.2+711.9%910.0%1494
$218.42-2.32%$122.3B18.3+312.2%771.2%1489
Sector avg-1.50%79.3+567.0%1032.6%1495